Literature DB >> 31582388

Diagnostic Accuracy and Scope of Intraoperative Transoral Ultrasound and Transoral Ultrasound-Guided Fine-Needle Aspiration of Retropharyngeal Masses.

T H Vu1, M Kwon2, S Ahmed2, M Gule-Monroe2, M M Chen2, J Sun3, B D Fornage4, J M Debnam2, B Edeiken-Monroe2.   

Abstract

The use of transoral sonography-guided fine-needle aspiration for intraoperative localization of retropharyngeal masses has been described by Fornage et al. The purpose of this study was to assess the accuracy of this technique. We reviewed the images and medical records of 26 patients with a retropharyngeal lesion suspicious for a metastatic lymph node of Rouviere identified on CT and/or PET/CT. There were 14 patients with a history of thyroid cancer, 7 with mucosal squamous cell carcinoma, 1 with renal cell carcinoma, 1 with parotid acinic cell cancer, 1 with metastatic colon adenocarcinoma, and 2 with no history of cancer. Intraoperative transoral sonography was performed using a commercially available endovaginal transducer. A transoral sonography-guided fine-needle aspiration was performed with a 25-cm-long 20-ga Chiba needle through a needle guide attached to the transducer shaft. Cytopathologic results were categorized as malignant, benign, or nondiagnostic. Transoral sonography and transoral sonography-guided fine-needle aspiration were performed in all patients. A diagnostic specimen was obtained in 25 of 26 (96%) patients with a 100% overall accuracy. Twelve patients underwent subsequent transoral resection of the retropharyngeal mass. In each patient, surgical pathology confirmed the fine-needle aspiration biopsy result. In 4 patients, transoral sonography-guided injection of methylene blue was used to facilitate intraoperative localization of the metastatic retropharyngeal mass. Transoral sonography and transoral sonography-guided fine-needle aspiration of suspicious masses in the retropharyngeal space are highly accurate procedures for identification and cytologic evaluation of benign and metastatic lymph nodes of Rouviere and for presurgical localization.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2019        PMID: 31582388      PMCID: PMC6975117          DOI: 10.3174/ajnr.A6236

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  7 in total

1.  CT-guided aspirations in the head and neck: assessment of the first 216 cases.

Authors:  Paul M Sherman; David M Yousem; Laurie A Loevner
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

2.  Magnetic resonance imaging--guided fine-needle aspiration biopsies of retropharyngeal lesions.

Authors:  E G Maghami; S Bonyadlou; B Larian; A Borges; E Abemayor; R B Lufkin
Journal:  Laryngoscope       Date:  2001-12       Impact factor: 3.325

3.  Use of transoral sonography with an endocavitary transducer in diagnosis, fine-needle aspiration biopsy, and intraoperative localization of retropharyngeal masses.

Authors:  Bruno D Fornage; Beth S Edeiken; Gary L Clayman
Journal:  AJR Am J Roentgenol       Date:  2014-05       Impact factor: 3.959

4.  Recurrent differentiated thyroid carcinoma: biological implications of age, method of detection, and site and extent of recurrence.

Authors:  Alexander Stojadinovic; Margo Shoup; Aviram Nissan; Ronald A Ghossein; Jatin P Shah; Murray F Brennan; Ashok R Shaha
Journal:  Ann Surg Oncol       Date:  2002-10       Impact factor: 5.344

5.  MRI-guided access to the retropharynx.

Authors:  Annie Lai; Ellie Maghami; Alexandra Borges; Shahram Bonyadilou; John Curran; Elliot Abemayor; Robert Lufkin
Journal:  J Magn Reson Imaging       Date:  2003-03       Impact factor: 4.813

6.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

7.  CT-guided percutaneous core biopsy of deep face and skull-base lesions.

Authors:  S E J Connor; N Chaudhary
Journal:  Clin Radiol       Date:  2008-07-07       Impact factor: 2.350

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.